Effect of adding GLP-1RA on mortality, cardiovascular events and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study
American Heart Journal Oct 13, 2017
Anyanwagu U, et al. - This study used a large UK database to compare the times to a major non-fatal cardiovascular (CV) event and all-cause mortality among overweight patients with Type 2 diabetes (T2D) treated with insulin alone versus insulin + GLP-1 receptor agonist (GLP-1RA). Findings revealed that insulin + GLP-1RA afforded a reduction in risk of composite CV events and all-cause mortality but non-significant higher risk of hospitalisation for heart failure in routine clinical practice.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
